CLAIMS

1. A backbone cyclized peptidic compound, built up from 13 amino acid residues, of the general formula

cyclo(-Xaa^1-Xaa^2-Thr^3-Xaa^4-Ser^5-Xaa^6-Xaa^7-Xaa^8-Xaa^9-Xaa^{10}-Xaa^{11}-Xaa^{12}-Xaa^{13}-)

(I),

and pharmaceutically acceptable salts thereof,

wherein

Xaa^1 is OctGly; Dab(Phe); Arg; Dab(Octanoyl); or Glu(Phe);

Xaa^2 is Glu; Phe; Dap(Phe); Val; or hTyr;

Xaa^4 is Ala; or AllylGly;

Xaa^6 is Ile;

Xaa^7 is Pro; Nglu; or Nlys;

Xaa^8 is Pro; Nglu; Nlys; Pip; Azt; or Oic;

Xaa^9 is Gln; or H-β^3-HGln-OH;

Xaa^{10} is Lys; H-β^3-HLys-OH; or H-γ^4-DiHLys-OH;

Xaa^{11} is hSer; hSer(Me); Thr; alloThr; hGln; Dap; Tyr; or H-γ^4-DiHTyr-OH; H-γ^4-DiHThr-OH; Ser; or Asn;

Xaa^{12} is ^{D}Pro; ^{D}Ala; ^{D}Val; ^{D}Tyr; ^{D}Lys; or ^{D}Ser; and

Xaa^{13} is Pro; ^{D}Pro; Oic; Ala; Tyr; Val; Lys; H-β^3-HPro-OH; ^{D}Glu; or Glu;

with the proviso that

- Xaa^1 is Dab(Phe); Dab(Octanoyl); or Glu(Phe); and/or
- Xaa^7 is Nglu; or Nlys; and/or
- Xaa^8 is Nglu; Nlys; Pip; Azt; or Oic; and/or
- Xaa^9 is H-β^3-HGln-OH; and/or
- Xaa^{10} is H-β^3-HLys-OH; or H-γ^4-DiHLys-OH; and/or
- Xaa^{11} is H-γ^4-DiHTyr-OH; or H-γ^4-DiHThr-OH; and/or
- Xaa^{12} is ^{D}Ala; ^{D}Val; ^{D}Tyr; ^{D}Lys; or ^{D}Ser; and/or
- Xaa^{13} is ^{D}Pro; Oic; H-β^3-HPro-OH; or ^{D}Glu;

and with the further proviso that

- if Xaa^{11} is Tyr, then

  Xaa^{1} is Dab(Phe); Arg; or Glu(Phe);

  and/or

  Xaa^{2} is Dap(Phe).

2. A compound according to claim 1 of the formula I wherein

Xaa^{1} is OctGly; or Dab(Phe);

Xaa^{2} is Glu;

Xaa^{4} is Ala;

Xaa^{6} is Ile;

Xaa^{7} is Pro; Nglu; or Nlys;

Xaa^{8} is Pro; Nglu; Nlys; Pip; or Azt;

Xaa^{9} is Gln; or H-β^{3}-HGln-OH;

Xaa^{10} is Lys; H-β^{3}-HLys-OH; or H-γ^{4}-DiHLys-OH;

Xaa^{11} is hSer; hSer(Me); Thr; alloThr; hGln; Dap; Tyr; or H-γ^{4}-DiHTyr-OH;

Xaa^{12} is ^{D}Pro; ^{D}Ala; ^{D}Val; ^{D}Tyr; or ^{D}Lys; and

Xaa^{13} is Pro; Oic; Ala; Tyr; or Val;

with the proviso that

- Xaa^{1} is Dab(Phe); and/or
- Xaa^{7} is Nglu; or Nlys; and/or
- Xaa^{8} is Nglu; Nlys; Pip; or Azt; and/or
- Xaa^{9} is H-β^{3}-HGln-OH; and/or
- Xaa^{10} is H-β^{3}-HLys-OH; or H-γ^{4}-DiHLys-OH; and/or
- Xaa^{11} is hSer; hSer(Me); alloThr; hGln; Dap or H-γ^{4}-DiHTyr-OH; and/or
- Xaa^{12} is ^{D}Ala; ^{D}Val; ^{D}Tyr; or ^{D}Lys; and/or
- Xaa^{13} is Oic;

and with the further proviso that

- if Xaa^{11} is Tyr, then

  Xaa^{1} is Dab(Phe).

3. A compound according to claim 1 of the formula I wherein

Xaa^{1} is OctGly; Arg; Dab(Octanoyl); or Glu(Phe);

Xaa^{2} is Glu; Phe; Dap(Phe); Val; or hTyr;

Xaa^{4} is Ala; or AllylGly;

Xaa^{6} is Ile;

Xaa^{7} is Pro;

Xaa^{8} is Pro; or Oic;

Xaa^{9} is Gln;

Xaa^{10} is Lys;

Xaa^{11} is Thr; H-γ^{4}-DiHThr-OH; Tyr;

Xaa^{12} is ^{D}Pro; ^{D}Val; ^{D}Tyr; ^{D}Lys; or ^{D}Ser; and

Xaa^{13} is Pro; ^{D}Pro; Lys; Val; Tyr; H-β^{3}-HPro-OH; ^{D}Glu; or Glu;

with the proviso that

- Xaa^{1} is Dab(Octanoyl); or Glu(Phe); and/or
- Xaa^{2} is Dap(Phe); and/or
- Xaa^{8} is Oic; and/or
- Xaa^{11} is H-γ^{4}-DiHThr-OH; and/or
- Xaa^{12} is ^{D}Val; ^{D}Tyr; ^{D}Lys; or ^{D}Ser; and/or
- Xaa^{13} is ^{D}Pro; H-β^{3}-HPro-OH; or ^{D}Glu;

and with the further proviso that

- if Xaa^{11} is Tyr, then

  Xaa^{1} is Arg; or Glu(Phe); and/or

  Xaa^{2} is Dap(Phe).

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Thr-^{D}Lys-Lys-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Thr-^{D}Lys-Glu-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Thr-^{D}Ser-Val-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Thr-^{D}Ser-Tyr-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Thr-^{D}Ser-Lys-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Nlys-Pro-Gln-Lys-Thr-^{D}Pro-Pro-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Nglu-Gln-Lys-Thr-^{D}Pro-Pro-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Nlys-Gln-Lys-Thr-^{D}Pro-Pro-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-[H-β^{3}-HGln-OH]-Lys-Thr-^{D}Pro-Pro-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-[H-β^{3}-HLys-OH]-Thr-^{D}Pro-Pro-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-[H-γ^{4}-DiHLys-OH]-Thr-^{D}Pro-Pro-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Thr-^{D}Pro-[H-β^{3}-HPro-OH]-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Thr-^{D}Pro-^{D}Glu-);

Cyclo(-Arg-Val-Thr-Ala-Ser-Ile-Pro-Oic-Gln-Lys-Thr-^{D}Pro-^{D}Pro-);

Cyclo(-Arg-hTyr-Thr-Ala-Ser-Ile-Pro-Oic-Gln-Lys-Thr-^{D}Pro-^{D}Pro-);

Cyclo(-Arg-hTyr-Thr-Ala-Ser-Ile-Pro-Oic-Gln-Lys-Thr-^{D}Pro-Glu-);

Cyclo(-Arg-Val-Thr-Ala-Ser-Ile-Pro-Oic-Gln-Lys-Thr-^{D}Pro-Glu-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Pip-Gln-Lys-Thr-^{D}Pro-Pro-);

Cyclo(-OctGly-Glu-Thr-Ala-Ser-Ile-Pro-Azt-Gln-Lys-Thr-^{D}Pro-Pro-);

Cyclo(-OctGly-hTyr-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Ser-^{D}Pro-Pro-);

Cyclo(-OctGly-hTyr-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Asn-^{D}Pro-Pro-);

Cyclo(-Arg-hTyr-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Thr-^{D}Pro-Glu-).

5. A compound according to anyone of claims 1 to 4, in free form or in pharmaceutically acceptable salt form, for use as a medicament.

6. A compound according to anyone of claims 1 to 4, in free form or in pharmaceutically acceptable salt form, having inhibitory activity against elastase for use in the treatment or prevention of lung cancer; breast cancer; psoriasis; alpha 1 antitrypsin deficiency; pulmonary emphysema; cystic fibrosis; chronic obstructive